These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 4005115)

  • 21. Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy.
    Davis SS; Washington N; Parr GD; Short AH; John VA; Lloyd P; Walker SM
    Br J Clin Pharmacol; 1988 Oct; 26(4):435-43. PubMed ID: 3056482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disposition of oxprenolol in spontaneously hypertensive rats as determined by an enzyme immunoassay.
    Kawashima K
    J Pharmacobiodyn; 1981 Jul; 4(7):534-40. PubMed ID: 7028945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers.
    Chan KK; Buch A; Glazer RD; John VA; Barr WH
    Pharm Res; 1994 Mar; 11(3):432-7. PubMed ID: 8008712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Jejunal and ileal absorption of oxprenolol in man: influence of nutrients and digestive secretions on jejunal absorption and systemic availability.
    Godbillon J; Vidon N; Palma R; Pfeiffer A; Franchisseur C; Bovet M; Gosset G; Bernier JJ; Hirtz J
    Br J Clin Pharmacol; 1987 Sep; 24(3):335-41. PubMed ID: 3663450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation.
    Kerr MJ; Harron DW; Kinney C; Shanks RG
    Br J Clin Pharmacol; 1981 Dec; 12(6):869-71. PubMed ID: 6122463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative bioavailability of different oral sustained release oxprenolol tablets.
    Leucuta SE; Follidis M; Capalneanu R; Mocan A
    Eur J Drug Metab Pharmacokinet; 1998; 23(2):178-84. PubMed ID: 9725478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis.
    Racine-Poon A; Moppert J
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):143S-149S. PubMed ID: 4005116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.
    Müller FB; Allsopp LF; Cooper GL; Bolli P; Frei P; Glaus L; Ritz R; Bühler FR
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):207S-212S. PubMed ID: 4005124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxprenolol: clinical pharmacology, pharmacokinetics, and pharmacodynamics.
    Kendall MJ; John VA
    Am J Cardiol; 1983 Nov; 52(9):27D-33D. PubMed ID: 6356863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of oxprenolol in the elderly.
    Kendall MJ
    Am J Cardiol; 1983 Nov; 52(9):54D-56D. PubMed ID: 6637853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of plasma and saliva levels of metoprolol and oxprenolol.
    Dawes CP; Kendall MJ; John VA
    Br J Clin Pharmacol; 1978 Mar; 5(3):217-21. PubMed ID: 656265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacokinetics and dynamics of oxprenolol: a simulation study with six subjects.
    Saunders L; Ingram D; Warrington SJ
    J Pharm Pharmacol; 1985 Nov; 37(11):802-6. PubMed ID: 2867161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of an in vitro faecal degradation method for early assessment of the impact of colonic degradation on colonic absorption in humans.
    Tannergren C; Borde A; Boreström C; Abrahamsson B; Lindahl A
    Eur J Pharm Sci; 2014 Jun; 57():200-6. PubMed ID: 24514453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro/in vivo characterization.
    Preda M; Leucuta SE
    J Microencapsul; 2003; 20(6):777-89. PubMed ID: 14594666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concentration-effect relationships for oxprenolol in patients with essential hypertension.
    McInnes GT; Brodie MJ
    Br J Clin Pharmacol; 1988 May; 25(5):539-45. PubMed ID: 3408634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Retention of metabolites of a beta-blocking drug, oxprenolol, in renal insufficiency].
    Dayer P; Glasson P; Gorgia A; Balant L; Fabre J
    Schweiz Med Wochenschr; 1981 Dec; 111(49):1915-8. PubMed ID: 7330645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absorption of rivastigmine from different regions of the gastrointestinal tract in humans.
    Lee L; Hossain M; Wang Y; Sedek G
    J Clin Pharmacol; 2004 Jun; 44(6):599-604. PubMed ID: 15145967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxprenolol placental transfer, plasma concentrations in newborns and passage into breast milk.
    Sioufi A; Hillion D; Lumbroso P; Wainer R; Olivier-Martin M; Schoeller JP; Colussi D; Leroux F; Mangoni P
    Br J Clin Pharmacol; 1984 Sep; 18(3):453-6. PubMed ID: 6487485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of oxprenolol on heart rate.
    Hedges A; Turner P
    Br Med J; 1973 Feb; 1(5850):422. PubMed ID: 4691086
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats.
    Kapetanovic IM; Muzzio M; McCormick DL; Thompson TN; Johnson WD; Horn TL; Mohammed A; Rao CV; Kopelovich L
    Cancer Chemother Pharmacol; 2012 May; 69(5):1301-6. PubMed ID: 22302406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.